Antiangiogenic and antitumor activities of berberine derivative NAX014 compound in a transgenic murine model of HER2/neu-positive mammary carcinoma

Carcinogenesis

Volumn 36, Issue 10, 2015, Pages 1169-1179

  Pierpaoli, Elisa ^a   Damiani, Elisa ^b   Orlando, Fiorenza ^a   Lucarini, Guendalina ^b   Bartozzi, Beatrice ^a   Lombardi, Paolo ^c,d   Salvatore, Carmela ^d   Geroni, Cristina ^d   Donati, Abele ^b   Provinciali, Mauro ^a  

^a INRCA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Naxospharma   (Italy)

^d Aesis Therapeutics Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

13 (4 CHLOROPHENYLETHYL)BERBERINE IODIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BERBERINE; BERBERINE DERIVATIVE; BETA GALACTOSIDASE; CD34 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANZYME B; HEPARANASE; MESSENGER RNA; PERFORIN; PROTEIN P16; UNCLASSIFIED DRUG; 13-(4-CHLOROPHENYLETHYL)BERBERINE; P16 PROTEIN, HUMAN; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER PREVENTION; CAPILLARY DENSITY; CELL AGING; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LD50; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MAMMARY NEOPLASMS, ANIMAL; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TRANSGENIC MOUSE;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BERBERINE; BERBERINE ALKALOIDS; BETA-GALACTOSIDASE; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ERBB-2;

EID: 84943773879     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgv103     Document Type: Article

References (35)

1. Ferlay, J. et al. (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer, 136, E359-E386.
2. Wang, H. et al. (2012) Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer. Agents Med. Chem., 12, 1281-1305.
3. Provinciali, M. et al. (2005) Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int. J. Cancer, 115, 36-45.
4. Provinciali, M. et al. (2007) Effect of the silybin-phosphatidylcholine complex (IdB 1016) on the development of mammary tumors in HER-2/neu transgenic mice. Cancer Res., 67, 2022-2029.
5. Pierpaoli, E. et al. (2013) Effect of annatto-tocotrienols supplementation on the development of mammary tumors in HER-2/neu transgenic mice. Carcinogenesis, 34, 1352-1360.
6. Imanshahidi, M. et al. (2008) Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother. Res., 22, 999-1012.
7. Guamán-Ortiz, L.M. et al. (2014) Berberine, an epiphany against cancer. Molecules, 19, 12349-12367.
8. Patil, J.B. et al. (2010) Berberine induces apoptosis in breast cancer cells (MCF-7) through mitochondrial-dependent pathway. Eur. J. Pharmacol., 645, 70-78.
9. Lin, C.C. et al. (2006) Apoptosis of human leukemia HL-60 cells and murine leukemia WEHI-3 cells induced by berberine through the activation of caspase-3. Anticancer Res., 26, 227-242.
10. Liu, Q. et al. (2015) Berberine induces senescence of human glioblastoma cells by downregulating the EGFR-MEK-ERK signaling pathway. Mol. Cancer Ther., 14, 355-363.
11. Hamsa, T.P. et al. (2012) Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators. Drug Chem. Toxicol., 35, 57-70.
12. Chu, S.C. et al. (2014) Berberine reverses epithelial-to-mesenchymal transition and inhibits metastasis and tumor-induced angiogenesis in human cervical cancer cells. Mol. Pharmacol., 86, 609-623.
13. Yan, L. et al. (2013) Berberine inhibits the migration and invasion of T24 bladder cancer cells via reducing the expression of heparanase. Tumour Biol., 34, 215-221.
14. Vlodavsky, I. et al. (2007) Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate. Curr. Pharm. Des., 13, 2057-2073.
15. Guamán Ortiz, L.M. et al. (2014) Multiple effects of berberine derivatives on colon cancer cells. Biomed Res. Int., 2014, 924585.
16. Lombardi, P. et al. (2012) Benzoquinolizinium salt derivatives as anticancer agents. U.S. Pat. 8, 188.
17. Anisimov, V.N. et al. (2005) Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp. Gerontol., 40, 685-693.
18. Pierpaoli, E. et al. (2010) Gamma-and delta-tocotrienols exert a more potent anticancer effect than alpha-tocopheryl succinate on breast cancer cell lines irrespective of HER-2/neu expression. Life Sci., 86, 668-675.
19. Goedhart, P.T. et al. (2007) Sidestream Dark Field (SDF) imaging: a novel stroboscopic LED ring-based imaging modality for clinical assessment of the microcirculation. Opt. Express, 15, 15101-15114.
20. Damiani, E. et al. (2015) Sidestream dark field videomicroscopy for in vivo evaluation of vascularization and perfusion of mammary tumours in HER2/neu transgenic mice. Clin. Exp. Pharmacol. Physiol., 42, 225-229.
21. Gilles, H.J. (1974) Calculation of the index of acute toxicity by the method of linear regression. Comparison with the method of "Karber and Behrens". Eur. J. Toxicol. Environ. Hyg., 7, 77-84.
22. Wang, H. et al. (2012) Plants against cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med. Chem., 12, 1281-1305.
23. Ananthula, S. et al. (2014) Oxazine derivatives of γ-and δ-tocotrienol display enhanced anticancer activity in vivo. Anticancer Res., 34, 2715-2726.
24. Ohori, H. et al. (2006) Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol. Cancer Ther., 5, 2563-2571.
25. Tillhon, M. et al. (2012) Berberine: new perspectives for old remedies. Biochem. Pharmacol., 84, 1260-1267.
26. Jabbarzadeh Kaboli, P. et al. (2014) Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. Eur. J. Pharmacol., 740, 584-595.
27. Letasiová, S. et al. (2006) Berberine-antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Lett., 239, 254-262.
28. Wu, H.L. et al. (1999) Berberine-induced apoptosis of human leukemia HL-60 cells is associated with down-regulation of nucleophosmin/B23 and telomerase activity. Int. J. Cancer, 81, 923-929.
29. Kheir, M.M. et al. (2010) Acute toxicity of berberine and its correlation with the blood concentration in mice. Food Chem. Toxicol., 48, 1105-1110.
30. Anis, K.V. et al. (1999) Role of berberine as an adjuvant response modifier during tumour therapy in mice. Pharmaceutical Pharmacology Communications, 5, 697-700.
31. Tsang, C.M. et al. (2013) Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts. BMC Cancer, 13, 619.
32. Choi, M.S. et al. (2009) Berberine inhibits p53-dependent cell growth through induction of apoptosis of prostate cancer cells. Int. J. Oncol., 34, 1221-1230.
33. Li, W. et al. (2014) Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice. Mol. Carcinog., doi:10.1002/mc.22179.
34. Muller, W.J. et al. (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 54, 105-115.
35. Lin, S. et al. (2004) Berberine inhibits HIF-1alpha expression via enhanced proteolysis. Mol. Pharmacol., 66, 612-619.